These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 16900111)

  • 1. Tysabri back on market.
    Sheridan C
    Nat Biotechnol; 2006 Aug; 24(8):874. PubMed ID: 16900111
    [No Abstract]   [Full Text] [Related]  

  • 2. MS drug back on market under restricted program.
    FDA Consum; 2006; 40(4):7. PubMed ID: 17243280
    [No Abstract]   [Full Text] [Related]  

  • 3. Tysabri risk causing headache for companies.
    Sheridan C
    Nat Rev Drug Discov; 2005 Sep; 4(9):703-4. PubMed ID: 16178114
    [No Abstract]   [Full Text] [Related]  

  • 4. Tysabri's troubles return.
    Hoag H
    Nat Biotechnol; 2008 Oct; 26(10):1061. PubMed ID: 18846062
    [No Abstract]   [Full Text] [Related]  

  • 5. Tysabri withdrawal calls entire class into question.
    Singer E
    Nat Med; 2005 Apr; 11(4):359. PubMed ID: 15812500
    [No Abstract]   [Full Text] [Related]  

  • 6. How Tysabri survived.
    Huggett B
    Nat Biotechnol; 2009 Nov; 27(11):986. PubMed ID: 19898447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natalizumab (Tysabri) returns.
    Med Lett Drugs Ther; 2006 Sep; 48(1243):76. PubMed ID: 16977289
    [No Abstract]   [Full Text] [Related]  

  • 8. Balancing risk and reward: the question of natalizumab.
    Hauser SL; Johnston SC
    Ann Neurol; 2009 Sep; 66(3):A7-8. PubMed ID: 19810091
    [No Abstract]   [Full Text] [Related]  

  • 9. [Natalizumab in multiple sclerosis].
    Rajda C; Bencsik K; Vécsei L;
    Ideggyogy Sz; 2008 May; 61(5-6):204-8. PubMed ID: 18567397
    [No Abstract]   [Full Text] [Related]  

  • 10. 'Biosimilar' drugs poised to penetrate market.
    Ledford H
    Nature; 2010 Nov; 468(7320):18-9. PubMed ID: 21048737
    [No Abstract]   [Full Text] [Related]  

  • 11. Tysabri raises alarm bells on drug class.
    Sheridan C
    Nat Biotechnol; 2005 Apr; 23(4):397-8. PubMed ID: 15815649
    [No Abstract]   [Full Text] [Related]  

  • 12. The trials and tribulations of Tysabri.
    Lancet Neurol; 2006 May; 5(5):373. PubMed ID: 16632299
    [No Abstract]   [Full Text] [Related]  

  • 13. The return of natalizumab: weighing benefit against risk.
    Goodin D
    Lancet Neurol; 2006 May; 5(5):375-7. PubMed ID: 16632301
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of multiple sclerosis].
    Holmøy T; Harbo HF; Celius EG
    Tidsskr Nor Laegeforen; 2010 May; 130(9):923; author reply 923. PubMed ID: 20453948
    [No Abstract]   [Full Text] [Related]  

  • 15. US drug approval ignores science's subtleties, experts say.
    Waltz E
    Nat Med; 2006 Apr; 12(4):373. PubMed ID: 16598269
    [No Abstract]   [Full Text] [Related]  

  • 16. MS drug withdrawn from market.
    FDA Consum; 2005; 39(3):3. PubMed ID: 16127808
    [No Abstract]   [Full Text] [Related]  

  • 17. CD20 blockers eye crowded rheumatology market.
    Mack GS
    Nat Biotechnol; 2008 Oct; 26(10):1053-4. PubMed ID: 18846053
    [No Abstract]   [Full Text] [Related]  

  • 18. The biotech drug market.
    Lawrence S
    Nat Biotechnol; 2004 Dec; 22(12):1496. PubMed ID: 15583645
    [No Abstract]   [Full Text] [Related]  

  • 19. Biotech jostles with pharma for slice of HIV market.
    Katsnelson A
    Nat Biotechnol; 2006 Jan; 24(1):3-4. PubMed ID: 16404375
    [No Abstract]   [Full Text] [Related]  

  • 20. Third Tysabri adverse case hits drug class.
    Sheridan C
    Nat Rev Drug Discov; 2005 May; 4(5):357-8. PubMed ID: 15902765
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.